Cabaletta Bio Investor Relations Material
Latest events
Status Update
Cabaletta Bio
Q2 2025
7 Aug, 2025
Investor Presentation
11 Jun, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cabaletta Bio Inc
Access all reports
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies designed to treat autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the Nasdaq.
Key slides for Cabaletta Bio Inc
Investor Presentation
Cabaletta Bio Inc
Investor Presentation
Cabaletta Bio Inc
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
CABA
Country
🇺🇸 United States